NCT03212911 is a Phase 4 clinical trial of Hepatitis B vaccine in Hepatitis B Vaccination, HIV, sponsored by Chiang Mai University.

Who is sponsoring NCT03212911?

NCT03212911 is sponsored by Chiang Mai University.

What drugs are being tested in NCT03212911?

Interventions in NCT03212911: Hepatitis B vaccine.

What condition does NCT03212911 study?

NCT03212911 studies Hepatitis B Vaccination, HIV.

Is NCT03212911 still recruiting?

NCT03212911 is currently status unknown. Last updated 11 July 2017.

Last reviewed 2017-07-11 · How we verify

NCT03212911

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HBV Vaccination in HIV-infected Adults

Status unknown Phase 4 Last updated 11 July 2017

What this trial tests

Phase 4 trial testing Hepatitis B vaccine in Hepatitis B Vaccination, HIV in 96 participants. Status unknown.

Timeline

1 July 2017

Primary endpoint
1 February 2018

1 July 2018

Quick facts

Lead sponsor	Chiang Mai University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	96
Start date	1 July 2017
Primary completion	1 February 2018
Estimated completion	1 July 2018
Sites	1 location across Thailand

Drugs / interventions tested

Hepatitis B vaccine — full drug profile →

Conditions studied

Hepatitis B Vaccination, HIV — all drugs for Hepatitis B Vaccination, HIV →

Sponsor

Chiang Mai University

Who can join

18 and older, any sex, with Hepatitis B Vaccination, HIV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The finding of isolated hepatitis B core antibody (isolated HBc) in absent of recent active hepatitis could cause by several scenarios, including false positive, remote infection without viremia, and occult infection with low viremia. Hepatitis B virus (HBV) vaccine booster could be a great prevention strategy for those who do not have HBV viremia. There is no standard consensus for management of this issue especially among HIV infected population. In addition, prior studies revealed that HIV-infected individuals had lower immunologic response to HBV vaccine than general population. This study intends to compare the immune response and safety of 4- versus 3-standard dose of hepatitis B virus vaccination in HIV-infected adults who has isolated HBc. The immunologic response will be evaluated after the participants receive vaccination.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Immunogenicity and safety of 4 vs. 3 standard doses of HBV vaccination in HIV-infected adults with isolated anti-HBc antibody.
Laksananun N, Praparattanapan J, Kotarathititum W, Supparatpinyo K, et al · · 2019 · cited 8× · PMID 31053142 · DOI 10.1186/s12981-019-0225-3

Verify or expand the search:

Other trials of Hepatitis B vaccine

Trials testing the same drug.

NCT06397768 — Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddler · Phase 3 · terminated
NCT02750202 — Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts · Phase 3 · completed
NCT03537508 — Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine · Phase 3 · completed
NCT03056924 — Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab · completed
NCT03219203 — Immunologic Response of Hepatitis B Vaccine · Phase 4 · unknown

Other Chiang Mai University trials

Trials by the same sponsor.

NCT07366775 — A Telenursing Program to Support Diabetes Self-Management · NA · active not recruiting
NCT07032610 — Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents · not yet recruiting
NCT06978621 — Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV · Phase 3 · recruiting
NCT06905041 — Preoperative Anemia Affected to Postoperative Outcomes in Liver Resection · not yet recruiting
NCT07476404 — Re-bleeding in Giant Meningioma and Intraoperative Hydroxyethyl Starch (HES) Fluid Therapy · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03212911 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chiang Mai University
Last refreshed: 11 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03212911.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing